Sirid Aimee Kellerman

Title: Sirid Aimee Kellerman: Innovator in Monoclonal Antibodies

Introduction

Sirid Aimee Kellerman is a prominent inventor based in Menlo Park, CA (US). She has made significant contributions to the field of biotechnology, particularly in the development of human monoclonal antibodies. With a total of 2 patents, her work has the potential to impact therapeutic approaches in various medical conditions.

Latest Patents

Kellerman's latest patents focus on human monoclonal antibodies to activin receptor-like kinase-1 (ALK-1). These inventions relate to antibodies that bind to the extracellular domain of ALK-1, effectively abrogating the ALK-1/TGF-beta-1/Smad1 signaling pathway. The patents also cover heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies, along with nucleic acid molecules encoding these immunoglobulins. Furthermore, the inventions include methods for producing human anti-ALK-1 antibodies, compositions comprising these antibodies, and methods for their application. Additionally, the patents discuss transgenic animals or plants that incorporate the nucleic acid molecules of the invention.

Career Highlights

Throughout her career, Kellerman has worked with leading companies in the biotechnology sector, including Pfizer Corporation and Amgen Fremont Inc. Her experience in these organizations has contributed to her expertise in the development of innovative therapeutic solutions.

Collaborations

Kellerman has collaborated with notable professionals in her field, including Michael Aidan North and James A Thomson. These partnerships have likely enhanced her research and development efforts.

Conclusion

Sirid Aimee Kellerman is a distinguished inventor whose work in monoclonal antibodies is paving the way for advancements in medical therapies. Her contributions to the field are noteworthy and continue to inspire innovation in biotechnology.